

JAKAVI - Home - HCP

[Prescribing information](#)

Image



Image



JAKAVI® (ruxolitinib)

JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.¹



JAKAVI® (ruxolitinib) in myelofibrosis

JAKAVI® (ruxolitinib) in myelofibrosis

See more details

Hide details



JAKAVI® (ruxolitinib) in polycythaemia vera

JAKAVI® (ruxolitinib) in polycythaemia vera

See more details

Hide details

Reference

1. JAKAVI® (ruxolitinib) Summary of Product Characteristics.

UK | November 2024 | FA-11208694

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL: <https://prod.pro.novartis.com/uk-en/medicines/haematology/jakavi>